Eton Pharmaceuticals (ETON) Price to Earnings (2018 - 2026)

Eton Pharmaceuticals has disclosed Price to Earnings across 9 years of filings, most recently posting 88.45 for Q2 2026.

• In Q2 2026, Price to Earnings rose 159.83% year-over-year to 88.45; the TTM figure through Jun 2026 stood at 107.25 (up 238.27% YoY), while the FY2025 annual figure was 127.01, down 65.01% from the prior year.
• Price to Earnings came in at 88.45 for Q2 2026 at Eton Pharmaceuticals, down from 184.2 in the prior quarter.
• In the past five years, Price to Earnings ranged from a high of 247.24 in Q3 2024 to a low of 302.41 in Q3 2025.
• Average Price to Earnings over 5 years is 50.57, with a median of 36.91 recorded in 2023.
• Year-over-year, Price to Earnings slumped 959.22% in 2023 and jumped 233.79% in 2024.
• Over 5 years, Price to Earnings stood at 25.48 in 2022, then sank by 295.74% to 49.87 in 2023, then plunged by 410.62% to 254.66 in 2024, then soared by 172.33% to 184.2 in 2025, then plunged by 51.98% to 88.45 in 2026.
• Per Business Quant data, the three most recent Price to Earnings figures were 88.45 in Q2 2026, 184.2 in Q4 2025, and 302.41 in Q3 2025.